Unknown

Dataset Information

0

Propranolol enhanced the anti-tumor effect of sunitinib by inhibiting proliferation and inducing G0/G1/S phase arrest in malignant melanoma.


ABSTRACT: Both sunitinib, a multi-target tyrosine kinase inhibitor (TKI) and propranolol, a non-selective ?-blocker, have proven therapeutic effects on malignant melanoma (MM). This study reports a synergistic effect of propranolol and sunitinib upon A375, P8 MM cell lines and mice xenografts. Cell viability assays detected a significant decrease of sunitinib IC50 in combination with propranolol, which was confirmed by a colony formation assay. Western blot showed that propranolol and sunitinib combination significantly down-regulated phospho-Rb, phospho-ERK, Cyclin D1, and Cyclin E, but had no effect on Bax, Bcl-2, or cleaved PARP expression. The average tumor size of propranolol and low-dose sunitinib (Sun L) combination treated mice was reduced and similar to high-dose sunitinib treated A375 xenografts. The Ki67 index was significantly reduced in propranolol and Sun L combination treated group compared with single Sun L treated group. This synergistic effect between propranolol and sunitinib to inhibit MM proliferation was through suppressing ERK/Cyclin D1/Rb/Cyclin E pathways and inducing G0/G1/S phase arrest, rather than by inducing tumor cell apoptosis.

SUBMITTER: Kuang X 

PROVIDER: S-EPMC5787512 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Propranolol enhanced the anti-tumor effect of sunitinib by inhibiting proliferation and inducing G0/G1/S phase arrest in malignant melanoma.

Kuang Xinwei X   Qi Min M   Peng Cong C   Zhou Chengfang C   Su Juan J   Zeng Weiqi W   Liu Hong H   Zhang Jianglin J   Chen Mingliang M   Shen Minxue M   Xie Xiaoyun X   Li Fangfang F   Zhao Shuang S   Li Qingling Q   Luo Zhongling Z   Chen Junchen J   Tao Juan J   He Yijing Y   Chen Xiang X  

Oncotarget 20171125 1


Both sunitinib, a multi-target tyrosine kinase inhibitor (TKI) and propranolol, a non-selective β-blocker, have proven therapeutic effects on malignant melanoma (MM). This study reports a synergistic effect of propranolol and sunitinib upon A375, P8 MM cell lines and mice xenografts. Cell viability assays detected a significant decrease of sunitinib IC50 in combination with propranolol, which was confirmed by a colony formation assay. Western blot showed that propranolol and sunitinib combinatio  ...[more]

Similar Datasets

| S-EPMC5356557 | biostudies-literature
| S-EPMC3639102 | biostudies-literature
| S-EPMC7509406 | biostudies-literature
| S-EPMC5022101 | biostudies-literature
| S-EPMC6566573 | biostudies-literature
| S-EPMC8126000 | biostudies-literature
| S-EPMC10631185 | biostudies-literature
| S-EPMC2766574 | biostudies-literature
| S-EPMC6158270 | biostudies-literature
| S-EPMC4442456 | biostudies-literature